71855-43-1

Upstream product

• 67-56-1 methanol 
• 63-84-3 dopa 
• 7101-51-1 (+/-)-3-(3,4-dihydroxyphenyl)-2-methyl-DL-alanine 
• 5796-17-8 D-Dopa 

Downstream Products

• 663601-61-4 2-Amino-3-(3,4-dioxo-cyclohexa-1,5-dienyl)-propionic acid methyl ester 
• 59-92-7 levodopa 
• 7101-51-1 L-DOPA methyl ester 
• 5796-17-8 D-Dopa 
• 626201-03-4 (R)-3-(3,4-Dihydroxy-phenyl)-2-[(E)-3-(3,4-dimethoxy-phenyl)-acryloylamino]-propionic acid methyl ester 
• 626201-07-8 (R)-3-(3,4-Dihydroxy-phenyl)-2-[(E)-3-(4-hydroxy-3-methoxy-phenyl)-allylamino]-propionic acid methyl ester 
• 618460-38-1 D-clovamide methyl ester 
• 626201-06-7 (R)-3-(3,4-Dihydroxy-phenyl)-2-[3-(3,4-dimethoxy-benzyl)-ureido]-propionic acid methyl ester 
• 118068-20-5 (1R,3R)-6,7-Dihydroxy-1-(3,4,5-trimethoxy-phenyl)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-benzyl ester 3-methyl ester 
• 118139-59-6 (6R,8R)-6-(3,4,5-Trimethoxy-phenyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carboxylic acid methyl ester 
• 118068-14-7 (6R,8R)-6-(3,4,5-Trimethoxy-phenyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carboxylic acid amide 
• 118067-89-3 (3aR,11R)-11-(3,4,5-Trimethoxy-phenyl)-3,3a,4,7,8,11-hexahydro-2,6,9-trioxa-1-thia-11a-aza-cyclopenta[b]anthracene 1-oxide 

Relevant academic research and scientific papers

Efficient and practical protection of the catechol residue of 3,4-dihydroxy-phenylalanine (DOPA) derivative as acetonide

The acetonide formation of 3,4-dihydroxyphenylalanine (DOPA) derivative was realized under efficient and practical reaction conditions: the reaction of the methyl ester of DOPA in acetone-i-PrOH in the presence of 5 mol% of TsOH afforded the catechol side chain protected DOPA as an acetonide in quantitative yield; the workup procedure is a simple evaporation of the solvents. This methodology allows an access to the reaction in large scale. Georg Thieme Verlag Stuttgart.

The structure-activity relationship of the series of non-peptide small antagonists for p56lck SH2 domain

The antagonists for the SH2 domain are regarded as novel therapeutic candidates for cancer, autoimmune disease, and chronic inflammatory disease. Previously, we identified rosmarinic acid (α-o-caffeoyl-3,4-dihydroxyphenyl-lactic acid; RosA) from Prunella vulgaris as an antagonist for the p56lck SH2 domain by screening natural products. RosA not containing phosphotyrosine surrogate had a considerable inhibitory activity for T-cell antigen receptor (TCR)-induced interleukin (IL)-2 expression, and subsequent T-cell proliferation in vitro cell assay. To investigate the structure-activity relationship of RosA and to identify a novel p56lck SH2 antagonist with more potent in vitro T-cell inhibitory activity, we synthesized several analogs of RosA by using rational design. All synthesized compounds were tested in vitro binding activity for the SH2 domain and in vitro T-cell inhibitory activity. All four hydroxyl groups of RosA were essential for binding with the p56lck SH2 domain and T-cell inhibitory activity. Unexpectedly, conformationally less constrained analogs 4 and 9 showed a more potent binding affinity for the SH2 domain than that of RosA, and chirality of the analog did not play an important role in protein binding. We successfully identified several RosA analogs with a more potent T-cell inhibitory activity than that of RosA. Overall results revealed important structural requirements of the p56lck SH2 antagonists for in vitro T-cell inhibitory activity and in vitro protein binding activity.

Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition

The present invention relates to derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition, more particularly the compounds of the present invention specifically inhibit the activation of T lymphocyte by src homology region 2(SH2) domain of T lymphocyte (lck), so that they can be used for the treatment, prevention and/or diagnosis of graft rejection, autoimmune diseases, inflammatory diseases, etc.

Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition

The present invention relates to derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition, more particularly the compounds of the present invention specifically inhibit the activation of T lymphocyte by src homology region 2(SH2) domain of T lymphocyte (lck), so that they can be used for the treatment, prevention and/or diagnosis of graft rejection, autoimmune diseases, inflammatory diseases, etc.

Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain

On the basis of the structure of (R)-rosmarinic acid, a series of small chemical compounds with a different scaffold was synthesized as inhibitors for lck SH2 domain. From ELISA results, most of all chemical compounds showed a similar or a little lower bi

Chemo-enzymatic synthesis of optically active amino acids and peptides

The industrial alkaline protease, alcalase, is stable and active in a high concentration of organic solvents and useful as a biocatalyst for (i) diastereoselective hydrolysis of peptide esters and preparation of racemization-free peptides; (ii) selective incorporation of esters of D-amino acid into peptides in t-butanol via a selective hydrolysis of esters of D,L-amino acid, followed by using the unhydrolyzed D-esters as a nucleophile in a kinetically controlled peptide bond formation; (iii) resolution of esters of amino acid in 95% t-butanol/5% water, followed by saponification of the unreacted esters to offer both enantiomers with high yield and optical purity; (iv) completely resolve amino-acid esters with high yield and optical purity via in situ racemization of the unreacted antipode catalyzed by pyridoxal 5-phosphate; (v) cryobioorganic synthesis of peptides with increased yields 15%-40% of peptide bond formation by reaction at 5 °C instead of 25-30 °C of a kinetically controlled enzymatic reaction in alcohols.

Synthesis of novel functionalised zinc phthalocyanines applicable in photodynamic therapy

The synthesis of several new phthalonitriles 3, 9, 14, 25, 33, and 36, functionalised with carboxyl groups, including two examples of amino acid derivatives is described. All new phthalonitriles were converted into their corresponding phthalocyaninatozinc compounds. The phthalocyanines, 2,3,9,10,16,17,23,24-octa(1-carboxyethyloxy)phthalocyaninatozinc (5), 2,9,16,23-tetra(2-amino-2-carboxyethyl)phthalocyaninatozinc (11), 2,9,16,23- tetra(1-carboxy-2-hydroxyethylaminocarbonyl)phthalocyaninatozinc (16), 1,8,15,22-tetra(carboxybutyl)phthalocyaninatozinc (27), 2,3,9,10,16,17,23,24- octa(carboxyalkyl)phthalocyaninatozinc (39), and the nonidentically substituted 9,10,16,17,23,24-hexa(carboxyalkyl)-2-[4-(N- succinimidyloxycarbonyl)butyl]phthaloyaninatozinc (41) are all sufficiently soluble in water. The nonidentically-substituted compounds are important due to their selective binding to tumor-selective antibodies. UV/Vis-spectroscopy was used to investigate the effect of more or less sterically-demanding substituents in the periphery of the phthalocyanines towards aggregation. The phototoxicity towards cancer cells of some of the new compounds was investigated in several in-vitro experiments.

Novel, transient pro-drug forms of L-DOPA

There is provided, novel, transient pro-drug forms of L-DOPA (3,4-dihydroxy-L-phenylalanine), having the formula: STR1 wherein n represents an integer of from 2 to 50 with respect to formula (V-A), and wherein n represents an integer of from 1 to 50 with respect to formula (V-B); R represents a hydrogen atom, an acyl group, STR2 --CO-pyridyl, or --CO--R3, wherein R3 is the residue of any N,N-C1 -C2 dialkylamino acid or a C4 -C6 cycloalkylamino acid; R1 represents --OH, --O-lower alkyl, --O-benzyl, or a naturally occurring protein amino acid; and R2 represents STR3 --CO-pyridyl, a naturally occurring protein amino acid, 3',4'-L-diacyloxy phenylalanine, or --CO-R3. These compounds are all useful in the treatment of Parkinson's Disease.